Protea Biopharma NV SA
Protea Biopharma NV reported total assets of €1.30m at the end of the 2023 financial year (annual accounts filed with the NBB on 29 Aug 2024).
The score of Protea Biopharma NV shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2023
Change 2020 → 2023: Total assets -9 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Protea Biopharma NV's annual accounts
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Net result | −44,940 € | ||||
| Equity | −999,054 € | ||||
| Cash | 3,072 € | ||||
| EBITDA | −42,800 € | ||||
| Total assets | €1.30m |
Filed annual accounts
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 31 Jul 2022
- Year ended 31 Dec 2020filed on 13 Jan 2022
- Year ended 31 Dec 2019filed on 31 Oct 2020
Protea Biopharma NV's financial analysis
- Solvency-76.9%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Protea Biopharma NV
Directors: in the full file.
Protea Biopharma NV's shareholders and holdings →Protea Biopharma NV's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0820.421.545
- VAT number
- BE0820421545
- Peppol
- Registered · 0208:0820421545 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 10 Nov 2009
- Registered office
- 1730 Asse
- Latest accounts
- 2023 · filed on 29 Aug 2024
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Protea Biopharma NV (SA) has been based in Asse since 2009, active in: research and experimental development on biotechnology. For 2023, it reports a net loss of 44,940 € and equity of −999,054 €; its revenue is not published. Its solvency stands at -76.9%, below the median of its sector (61.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Protea Biopharma NV
Companies in the same business, of comparable size and area, outside its group.
- Inhatarget Therapeutics Research and experimental development on natural sciences and engineering Charleroi · balance sheet €2.16m
- Abaxys Therapeutics Research and experimental development on natural sciences and engineering Villers-la-Ville · balance sheet €1.31m
- Novobiom Research and experimental development on natural sciences and engineering Liège · balance sheet €3.92m
- Stam Agro Research and experimental development on natural sciences and engineering Dendermonde · balance sheet €1.86m
- Biostrand Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 804,186 €
- Clenio Research and experimental development on natural sciences and engineering Liège · balance sheet 884,617 €
- Celyad Oncology Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €4.03m
- Aneurotech Research and experimental development on natural sciences and engineering Alken · balance sheet €2.91m
Frequently asked questions about Protea Biopharma NV
What is the revenue of Protea Biopharma NV?
Protea Biopharma NV files its accounts in a format where revenue is optional: it is not published for 2023.
What is the VAT number of Protea Biopharma NV?
In Belgium, the VAT number is the company number prefixed with BE: BE0820421545 for Protea Biopharma NV, if the company is VAT-registered. Its company number (CBE) is 0820.421.545.
Where is the registered office of Protea Biopharma NV?
According to the CBE register, the registered office of Protea Biopharma NV is in 1730 Asse.
What is the equity of Protea Biopharma NV?
At the close of the 2023 financial year, the equity of Protea Biopharma NV amounts to -999,054 €, a solvency of -76.9% of total assets.
The full file of Protea Biopharma NV
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →